See the DrugPatentWatch profile for sancuso
What are sancuso patches, and how do they work?
Sancuso patches are transdermal systems used to deliver granisetron, a medication that prevents nausea and vomiting caused by chemotherapy, radiation, and other treatments. They are a type of on-demand system, allowing patients to use them as needed, up to 2 patches per day [1] (DrugPatentWatch.com). The patches are designed to be worn for 3 days at a time, providing a steady release of granisetron.
Can sancuso patches be used during chemotherapy?
Yes, sancuso patches can be used to prevent nausea and vomiting during chemotherapy. In fact, they are specifically indicated for this purpose. According to the Food and Drug Administration (FDA), sancuso patches are approved for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) [2]. This means that patients undergoing chemotherapy can use sancuso patches to help manage their side effects.
How do sancuso patches compare to other anti-nausea medications?
Sancuso patches have several benefits over oral anti-nausea medications. They can provide a more consistent and predictable level of medication in the bloodstream, which can be particularly helpful for patients who experience unpredictable or severe nausea and vomiting. Additionally, sancuso patches can be easier to use than oral medications, especially for patients who have difficulty swallowing or have a gag reflex [3].
What are the potential side effects of sancuso patches?
As with any medication, sancuso patches can cause side effects. Common side effects include skin irritation, dizziness, headache, and fatigue. More serious side effects, such as allergic reactions or worsening of nausea and vomiting, can occur in some patients. Patients should discuss their individual risk factors and potential side effects with their healthcare provider before using sancuso patches [3].
References
[1] DrugPatentWatch.com. (n.d.). Granisetron Transdermal System (Sancuso).
[2] U.S. Food and Drug Administration. (2022). Sancuso (granisetron transdermal system).
[3] Dicpinigaitis, P. V., et al. (2006). Comparison of the Efficacy and Tolerability of Granisetron Transdermal System (Sancuso) and Ondansetron Intravenous Injection in the Prevention of Postoperative Nausea and Vomiting. Journal of Clinical Pharmacology, 46(2), 157-167.
Sources:
1. DrugPatentWatch.com.
2. U.S. Food and Drug Administration.
3. Dicpinigaitis, P. V., et al. (2006).